Sphingolipid targets in cancer therapy

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 200-208

  Modrak, David E ^a   Gold, David V ^a   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; 2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ACYLSPHINGOSINE DEACYLASE; ANTINEOPLASTIC AGENT; B 13; CERAMIDE; CYTARABINE; CYTOKINE; DEOXYGALACTONOJIRIMYCIN; DOXORUBICIN; ERYTHRO 2 (N MYRISTOYLAMINO) 1 PHENYL 1 PROPANOL; ETOPOSIDE; FAS ANTIGEN; FLUOROURACIL; GEMCITABINE; LIPOSOME; N,N DIMETHYLSPHINGOSINE; NOJIRIMYCIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SAFINGOL; SPHINGOLIPID; SPHINGOMYELIN; THERMOZYMOCIDIN; THREO 1 PHENYL 2 PALMITOYLAMINO 3 MORPHOLINO 1 PROPANOL; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; TRIMETHYLSPHINGOSINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL LEVEL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG EXPOSURE; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LD 50; LIPID ANALYSIS; LIPOGENESIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SARCOMA; SECOND MESSENGER; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CERAMIDES; HUMANS; NEOPLASMS; SPHINGOLIPIDS;

EID: 33644977905     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0420     Document Type: Review

References (73)

1. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002;110:3-8.
2. Radin NS. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur J Biochem 2001;268:193-204.
3. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002;1585: 114-25.
4. Birbes H, Bawab SE, Obeid LM, Hannun YA. Mitochondria and ceramide: intertwined roles in regulation of apoptosis. Adv Enzyme Regul 2002;42:113-29.
5. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16.
6. Tepper AD, Ruurs P, Wiedmer T, Sims PJ, Borst J, van Blitterswijk WJ. Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology. J Cell Biol 2000;150:155-64.
7. Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA, Brenner DA. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem 2005;280:27879-87.
8. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82:405-14.
9. Merrill AH, Jr., Schmelz EM, Wang E, Schroeder JJ, Dillehay DL, Riley RT. Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. J Nutr 1995;125:1677-82S.
10. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86:189-99.
11. Goulding CW, Giuliano AE, Cabot MC. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 2000;149:143-51.
12. Bielawska A, Greenberg MS, Perry D, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 1996;271:12646-54.
13. Selzner M, Bielawska A, Morse MA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001;61:1233-40.
14. Bleicher RJ, Cabot MC. Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002;1585:172-8.
15. Goñi FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 2002;531:38-46.
16. Gulbins E, Grassme H. Ceramide and cell death receptor clustering. Biochim Biophys Acta 2002;1585:139-45.
17. Tomiuk S, Zumbansen M, Stoffel W. Characterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinase. J Biol Chem 2000;275:5710-7.
18. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001;31:717-28.
19. Schmelz EM, Merrill AH, Jr. Ceramides and ceramide metabolites in cell regulation: evidence for dietary sphingolipids as inhibitors of colon carcinogenesis. Nutrition 1998;14:717-9.
20. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharm Res 2003;47:383-92.
21. Zhang Y, Yao B, Delikat S, et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997;89:63-72.
22. Ruvolo PP, Gao F, Blalock WL, Deng X, May WS. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J Biol Chem 2001;276:11754-8.
23. Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 1994;269:19605-9.
24. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993;268: 15523-30.
25. Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277:22847-52.
26. Huwiler A, Johansen B, Skarstad A, Pfeilschifter J. Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J 2001;15: 7-9. Order.
27. De Stefanis D, Reffo P, Bonelli G, et al. Increase in ceramide level alters the lysosomal targeting of cathepsin D prior to onset of apoptosis in HT-29 colon cancer cells. Biol Chem 2002;383:989-99.
28. Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J Biol Chem 1997;272:9609-12.
29. Veldman RJ, Maestre N, Aduib OM, Medin JA, Salvayre R, Levade T. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem J 2001;355:859-68.
30. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy [review]. Int J Oncol 1998;12:141-52.
31. Birbes H, El Bawab S, Hannun YA, Obeid LM. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis. FASEB J 2001; 15:2669-79.
32. von Haefen C, Wieder T, Gillissen B, et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 2002;21:4009-19.
33. Gudz TI, Tserng KY, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997;272:24154-8.
34. Shimeno H, Soeda S, Sakamoto M, Kouchi T, Kowakame T, Kihara T. Partial purification and characterization of sphingosine N-acyltransferase (ceramide synthase) from bovine liver mitochondrion-rich fraction. Lipids 1998;33:601-5.
35. El Bawab S, Roddy P, Qian T, Bielawska A, Lemasters JJ, Hannun YA. Molecular cloning and characterization of a human mitochondrial ceramidase. J Biol Chem 2000;275:21508-13.
36. Martelli AM, Fala F, Faenza I, et al. Metabolism and signaling activities of nuclear lipids. Cell Mol Life Sci 2004;61:1143-56.
37. Albi E, Micheli M, Viola Magni MP. Phospholipids and nuclear RNA. Cell Biol Int 1996;20:407-12.
38. Modrak DE, Jones G, Draper MP. Genomic instability and the microenvironment in the evolution of drug resistance in cancer. In: White D, Alekshun M, McDermott, editors. Frontiers in Antibiotic Resistance. Philadelphia (PA): American Society for Microbiology; 2005. p. 500-13.
39. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000;95:2897-904.
40. Raggers RJ, van Helvoort A, Evers R, van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci 1999;112:415-22.
41. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses Adriamycin resistance. J Biol Chem 2000;275: 7138-43.
42. Norris-Cervetto E, Callaghan R, Platt FM, Dwek RA, Butters TD. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J Biol Chem 2004;279:40412-8.
43. Miro Obradors MJ, Sillence D, Howitt S, Allan D. The subcellular sites of sphingomyelin synthesis in BHK cells. Biochim Biophys Acta 1997; 1359:1-12.
44. Allan D, Quinn P. Resynthesis of sphingomyelin from plasma-membrane phosphatidylcholine in BHK cells treated with Staphylococcus aureus sphingomyelinase. Biochem J 1988;254:765-71.
45. Marsh BJ, Mastronarde DN, Buttle KF, Howell KE, McIntosh JR. Organellar relationships in the Golgi region of the pancreatic beta cell line, HIT-T15, visualized by high resolution electron tomography. Proc Natl Acad Sci U S A 2001;98:2399-406.
46. Koval M, Pagano RE. Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta 1991;1082:113-25.
47. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002; 1585:193-201.
48. Pitson SM, Xia P, Leclercq TM, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005;201:49-54.
49. Kariya Y, Kihara A, Ikeda M, et al. Products by the sphingosine kinase/sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis. Genes Cells 2005;10:605-15.
50. Stoffel W, LeKim D, Sticht G. Distribution and properties of dihydrosphingosine-1-phosphate aldolase (sphinganine-1-phosphate alkanal-lyase). Hoppe Seylers Z Physiol Chem 1969;350:1233-41.
51. De Ceuster P, Mannaerts GP, Van Veldhoven PP. Identification and subcellular localization of sphinganine-phosphatases in rat liver. Biochem J 1995;311:139-46.
52. Hinkovska-Galcheva V, Boxer LA, Kindzelskii A, et al. Ceramide 1-phosphate, a mediator of phagocytosis. J Biol Chem 2005;280: 26612-21.
53. Boudker O, Futerman AH. Detection and characterization of ceramide-1-phosphate phosphatase activity in rat liver plasma membrane. J Biol Chem 1993;268:22150-5.
54. Meyer zu Heringdorf D, Himmel HM, Jakobs KH. Sphingosylphosphorylcholine-biological functions and mechanisms of action. Biochim Biophys Acta 2002;1582:178-89.
55. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002;3:1652-9.
56. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995;211: 396-403.
57. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005;108:308-19. Epub 2005 Jun 13.
58. Schwartz GK, Ward D, Saltz L, et al. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997;3:537-43.
59. Shirahama T, Sweeney EA, Sakakura C, et al. In vitro and in vivo induction of apoptosis by sphingosine and N, N- dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin Cancer Res 1997;3:257-64.
60. Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N N-dimethyl and N N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991;51:1613-8.
61. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005;11:3465-74.
62. Shabbits JA, Mayer LD. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res 2003;23:3663-9.
63. Kandyba AG, Kobliakov VA, Somova OG, Dyatlovitskaya EV. Change in contents of biologically active sphingolipids modulating cell growth and survival in hepatoma 27 compared to rat liver. Biochemistry (Mosc) 2004; 69:497-500.
64. Koizumi K, Tamiya-Koizumi K, Fujii T, Okuda J, Kojima K. Comparative study of the phospholipid composition of plasma membranes isolated from rat primary hepatomas induced by 3′-methyl-4- dimethylaminoazobenzene and from normal growing rat livers. Cancer Res 1980; 40:909-13.
65. Modrak DE, Lew W, Goldenberg DM, Blumenthal R. Sphingomyelin potentiates chemotherapy of human cancer xenografts. Biochem Biophys Res Commun 2000;268:603-6.
66. Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res 2004;64:8405-10.
67. Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int J Oncol 2002;20:379-84.
68. Schmelz EM, Sullards MC, Dillehay DL, Merrill AH, Jr. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. J Nutr 2000;130:522-7.
69. Chua CW, Lee DT, Ling MT, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 2005;117:1039-48.
70. Schmid G, Guba M, Papyan A, et al. FTY720 inhibits tumor growth and angiogenesis. Transplant Proc 2005;37:110-1.
71. Loor F. Valspodar: current status and perspectives. Expert Opin Investig Drugs 1999;8:807-35.
72. Guerrera M, Ladisch S. N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett 2003;201:31-40.
73. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11:1910-7.